Wasting Syndrome:Oral Oxandrolone Re-released in U.S.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Wasting Syndrome:Oral Oxandrolone Re-released in U.S.

AIDS Treatment News (12/22/95) No.237, P. 3
James, John S.

Abstract: The oral anabolic steroid oxandrolone, which may offer one way to treat wasting syndrome, became available again in the United States in December 1995. Oxandrolone is not primarily metabolized in the liver, and like other anabolic steroids, works by promoting the synthesis of proteins. Wasting syndrome involves the abnormal loss of protein and lean body mass. Although oxandrolone was approved by the U.S. Food and Drug Administration (FDA) more than 30 years ago to promote weight gain to replace weight lost due to infectious illness, U.S. companies stopped offering the drug instead of meeting the increasing mandatory regulations. Bio-Technology General Corp., a small drug company, has re-released oxandrolone for weight gain, and is researching its use for 4 other conditions, which it now has orphan-drug status for, including AIDS wasting.

960112
AD960073

Copyright © 1996 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.